Benchling software that powers many biotech startups and more than half of the top 50 global biopharma companies. Over 200,000 scientists rely on the Benchling R&D Cloud as their central source of truth for scientific data, analysis and collaboration. 

Sanofi is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo.

Benchling is working with Sanofi to transition from legacy R&D systems to a digital platform through Benchling R&D Cloud; this is an integral process to enable Sanofi’s AI-powered R&D ambition. As a result of the partnership, its R&D teams are able to scale and accelerate groundbreaking research processes in just hours instead of weeks.

Benchling R&D Cloud is used by teams across Sanofi, including early discovery-omics such as precision oncology, core therapeutic pipeline teams including novel modalities like mRNA, all the way up the lifecycle to translational teams. Through Benchling’s R&D Cloud, complex data from various departments at Sanofi is aggregated, enabling better decision-making, analytics, and collaboration. This real-time visibility into standardized data across teams gives Sanofi high-quality inputs to gain new insight faster.

“Sanofi is paving the way for a new era of biotechnology, where every stage of R&D is faster, smarter, and more automated,” said Sajith Wickramasekara, CEO and co-founder Benchling. “Sanofi’s adoption of Benchling unlocks their ability to harness AI. With our R&D Cloud, Sanofi scientists can do their best work and accelerate timelines for life-changing medicines.”